申请人:Sunovion Pharmaceuticals Inc.
公开号:US11129807B2
公开(公告)日:2021-09-28
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
本文提供的方法用于确定化合物是否对治疗精神分裂症的特定症状域具有潜在疗效,例如治疗精神分裂症的阴性症状。此外,本文还提供了确定精神分裂症患者突出症状域的方法。此外,本文还提供了治疗与精神分裂症相关的阴性症状、认知功能障碍症状或两者的各种方法,包括向受试者施用治疗或预防有效量的各种化合物。